We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Cannabinoid Technologies Holdings Plc | LSE:OCTP | London | Ordinary Share | GB00BMVMRB86 | ORD GBP0.001 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.115 | 0.10 | 0.13 | - | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 0 | -5.95M | -0.0062 | -0.18 | 1.1M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 16/5/2023 13:26 | Tick tok times ticking and no news hmmmm | itscominghome | |
| 16/5/2023 12:03 | Hi there, does anyone know how octp intend to finance the operation between the end of this year when they run out of funds and 2027 when the lead product is due to go commercial? Many thanks | merv_j | |
| 12/5/2023 09:17 | get ready rocket to moon | zxie | |
| 12/5/2023 09:17 | RNS in may | zxie | |
| 12/5/2023 08:47 | Hopefully you're right, good news on a Friday never has legs due to the weekend cool off period. | sweetg | |
| 12/5/2023 07:42 | Hope I'm proven wrong | jasko | |
| 12/5/2023 07:41 | Looks like it's not today:-) | jasko | |
| 10/5/2023 14:49 | Took off today. Regards, F911 RMC | firestorm911 | |
| 10/5/2023 10:31 | Oh goodness | zxie | |
| 10/5/2023 10:14 | She's teasing us on a daily basis:-) | jasko | |
| 10/5/2023 09:32 | RNS any time | zxie | |
| 10/5/2023 09:25 | about to break | jambam | |
| 09/5/2023 08:40 | https://www.express. | zxie | |
| 05/5/2023 10:07 | RNS next week | zxie | |
| 05/5/2023 07:28 | loading up | soultrading | |
| 04/5/2023 06:48 | This Phase I first-in-human clinical trial, due to commence in Q1 2023, which is being funded entirely from OCTP's existing resources, will be conducted in the UK in healthy volunteers, with a single ascending dose. The trial aims to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. The clinical trial is anticipated to complete within Q2 2023. | zxie | |
| 03/5/2023 13:53 | Tomorrow could be here | zxie | |
| 03/5/2023 13:05 | Good shs. Regards, F911 RMC | firestorm911 | |
| 03/5/2023 12:41 | https://twitter.com/ | zxie | |
| 03/5/2023 09:10 | Let go . Jump up | zxie | |
| 03/5/2023 08:56 | Good morning all my friends Looking to buy buy buy to 2.0p today. Enjoy!! Regards F911 RMC | firestorm911 | |
| 02/5/2023 13:15 | You're so sweet | zxie | |
| 02/5/2023 07:53 | https://twitter.com/ | zxie |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
